Literature DB >> 12962815

Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990-1999.

O Alonso1, C Loinaz, M Abradelo, B Pérez, A Manrique, R Gómez, C Jiménez, J C Meneu, I García, E Moreno-González.   

Abstract

BACKGROUND/AIM: Changes in immunosuppression and other factors may have changed the severity of recurrent hepatitis C during recent years. This study sought to establish the changes in incidence and severity of recurrent hepatitis C, and its association with the changes in acute rejection and induction immunosuppressive therapy between 1990 and 1999. PATIENTS AND METHODS: Among 213 liver transplants in HCV-infected recipients, 129 grafts were selected for this study: all grafts with severe recurrent hepatitis C (fibrosis 3-4 in Scheuer's score or fibrosing cholestatic hepatitis), and those grafts without severe recurrence with at least 2 years of follow up. Grafts were divided in 5 groups depending on the year of transplantation to compare recurrent hepatitis C-related variables, AR incidence and induction immunosuppression.
RESULTS: Hepatitis-free survival decreased in recent years (p=0.015). The incidence of fibrosing cholestatic hepatitis was higher among 1996-1997 and the 1998-1999 periods (p=0.019). Survival free of severe hepatitis at 1 year follow up was 95% in 1990-1991 and 80% in 1998-1999; however, in the long-term the survival was similar between groups (p=0.933). HCV-related graft survival at 5 years was 93.5% in the 1990-95 period and 82.5% in 1996-99 (p=0.068). Neither AR nor any regimen of induction immunosuppression was associated with changes in the occurrence of recurrent hepatitis C related survival.
CONCLUSIONS: Severity of recurrent hepatitis C and HCV-related graft loss after liver transplantation were higher in the second half of the 1990s; however, there was no association with AR or induction immunosuppression.

Entities:  

Mesh:

Year:  2003        PMID: 12962815     DOI: 10.1016/s0041-1345(03)00604-3

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.

Authors:  Mark W Russo; Tarun Narang; Lon Eskind; Daniel Hayes; Vincent Casingal; Preston P Purdum; John S Hanson; Will Ahrens; James Norton; Herbert Bonkovsky
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

2.  Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.

Authors:  Mohamed Shoreibah; Jordan Orr; DeAnn Jones; Jie Zhang; Krishna Venkata; Omar Massoud
Journal:  Hepatol Int       Date:  2017-01-12       Impact factor: 9.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.